Furthermore, transient PARPi treatment upregulates STAT3 activation in mouse and human immune cells, leading to enhanced production of immunosuppressive cytokines and reduced expression of immuno-stimulating factors required for T cell-mediated killing of tumor cells. The gene discussed is STAT3; the disease is neoplasm.